# Terje R. Pedersen

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/terje-r-pedersen/

## Facts

| Field | Value |
| --- | --- |
| Citations | 61,167 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 85 |
| i10-index | 164 |
| OpenAlex ID | https://openalex.org/A5111756488 |
| ORCID iD | https://orcid.org/0000-0003-3975-5390 |
| Works | 246 |

## Researcher papers

- [2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i>](https://scholariq.org/papers/2019-esc-eas-guidelines-for-the-management-of-dyslipidaemias-i-lipid/)
- [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease](https://scholariq.org/papers/evolocumab-and-clinical-outcomes-in-patients-with-cardiovascular-disease/)
- [Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials](https://scholariq.org/papers/statins-and-risk-of-incident-diabetes-a-collaborative-meta-analysis-of/)
- [Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)](https://scholariq.org/papers/cholesterol-lowering-with-simvastatin-improves-prognosis-of-diabetic-patients/)
- [Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes](https://scholariq.org/papers/early-intensive-vs-a-delayed-conservative-simvastatin-strategy-in-patients-with/)
- [Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins](https://scholariq.org/papers/association-of-ldl-cholesterol-non-hdl-cholesterol-and-apolipoprotein-b-levels/)
- [Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial](https://scholariq.org/papers/cardiovascular-safety-and-efficacy-of-the-pcsk9-inhibitor-evolocumab-in-patients/)
- [Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events](https://scholariq.org/papers/very-low-levels-of-atherogenic-lipoproteins-and-the-risk-for-cardiovascular/)
- [Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol](https://scholariq.org/papers/comparison-of-ranibizumab-and-bevacizumab-for-neovascular-age-related-macular/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.